Earnings guidance change and new partnership set the context for Vertex Pharmaceuticals stock

Vertex Pharmaceuticals (VRTX) recently reported second quarter 2026 results, updated its full year revenue guidance, and announced a new collaboration with AbCellera Biologics on multispecific T cell engagers for autoimmune diseases.

Vertex Pharmaceuticals has seen steady positive momentum, with the share price at US$496.07 and a 90 day share price return of 13.99%. The 1 year total shareholder return of 35.34% sits well ahead of its 9.72% year to date share price return, suggesting strong longer term gains that recent earnings and guidance news may be helping to sustain.

If you are looking for other healthcare names exposed to similar themes, this is a good moment to scan 43 healthcare AI stocks. You might uncover companies that align with your view on medical technology and treatment advances.

Vertex Pharmaceuticals now trades after a strong year of gains and a fresh bump to guidance. Are you mainly seeing a repricing of sentiment, or a valuation that better lines up with the business just reported?

Most Popular Narrative: 11.2% Undervalued

The most followed narrative for Vertex Pharmaceuticals puts fair value at $558.68, above the recent $496.07 close, and builds that gap on specific growth and margin assumptions.

Vertex's pipeline diversification, including programs in pain, kidney, and type 1 diabetes, leverages global advances in genomic and gene-editing technologies, positioning the company to capture long-term growth from accelerating personalized and precision medicine adoption, supporting both revenue and long-term margin expansion.

Read the complete narrative. Read the complete narrative.

Want to see how this view justifies a higher fair value for Vertex Pharmaceuticals? The narrative leans on compounded revenue growth, rising profit margins and a premium future earnings multiple. Curious which assumptions matter most and how they stack up against today’s earnings base? The full breakdown lays out the numbers behind that $558.68 figure.

Result: Fair Value of $558.68 (UNDERVALUED)

However, this Vertex Pharmaceuticals narrative still hinges on successful execution beyond cystic fibrosis, as well as on managing pricing pressure that could squeeze future margins and cash generation.

Another View on Vertex Pharmaceuticals valuation

The analyst narrative and SWS work suggest Vertex Pharmaceuticals is trading about 12.2% below an estimated fair value of $565.15 based on our DCF model. That still contrasts with a P/E of 28.5x, which screens above the US Biotechs average of 17.2x and slightly above the 27.8x fair ratio. As an investor, how much weight do you put on cash flow modelling versus current earnings multiples?

Our DCF model is only one lens on Vertex Pharmaceuticals, and it rests on specific growth, margin and discount rate inputs. If you want to see how each of those pieces feeds into the fair value output, Look into how the SWS DCF model arrives at its fair value.

Next Steps

With the tone of this Vertex Pharmaceuticals update in mind, it makes sense to move quickly, review the full data set and decide what holds up for you. To see which potential rewards investors are focusing on right now, take a closer look at the 3 key rewards.

Looking for more investment ideas beyond Vertex Pharmaceuticals?

If you stop with Vertex Pharmaceuticals, you could miss stocks that better match your risk tolerance and income goals. Use the Simply Wall St screener to test fresh ideas fast.

• Target resilient balance sheets and fundamentals by checking companies in the solid balance sheet and fundamentals stocks screener (48 results), which may handle tougher conditions more comfortably.
• Hunt for potential value opportunities by scanning the 52 high quality undervalued stocks, which pair quality fundamentals with prices that look out of sync with their metrics.
• Build a steadier income stream by reviewing the 8 dividend fortresses, which focus on higher yielding stocks with an eye on sustainability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.